Aussie medical tech scores big win in US market

Cyclopharm’s lung imaging technology is breathing new life into the company’s bottom line, with its Technegas product surpassing the million-dollar milestone in US sales, according to Tuesday’s ASX announcement. The Sydney-based company has rapidly expanded its American footprint, with Technegas systems now installed in 27 US medical facilities as of 31 March 2025 – a…

Technegas’ new use in lung transplant imaging

Radiopharmaceutical medical imaging manufacturer Cyclopharm has revealed a possible new use for its Technegas system – for evaluating the progress of lung transplantation. The use is detailed in a US-based study which highlights the clinical utility and operational benefits of the Technegas technology compared to current US ventilation imaging radiopharmaceuticals used in lung transplant evaluation.…

entX to decide on radiopharmaceutical, defence facility in 2024

Radiopharmaceutical developer entX Ltd is poised to make a decision to green light construction of a radiopharmaceutical production facility targeting cancer treatment with radioactive isotopes. The facility is supported by a $1.9 million Economic Recovery Fund (ERF) grant from the South Australian Government as well as a $2,915,000 Cooperative Research Centres Projects (CRC-P) grant announced…

Cyclopharm breaks into US defence veterans market

Radiopharmaceutical system manufacturer Cyclopharm has entered into an agreement to supply the Veterans Health Administration (VA), the largest US government health care system, with the pharmaceutical and consumable components of its Technegas imaging system. The Interim Agreement immediately provides the 120 Veterans Affairs hospitals, which have nuclear medicine departments, access to an agreed contract for…